Palbociclib Fails to Prevent Recurrence After Neoadjuvant Therapy in HR+/HER2-Breast Cancer

In an update from the phase III PENELOPE-B trial, palbociclib did not improve invasive disease-free survival when added to endocrine therapy in patients with HR-positive, HER2-negative breast cancer who were considered to be at high risk for recurrence following neoadjuvant chemotherapy.

Automated summary

In the phase III PENELOPE-B trial, it was found that palbociclib did not improve invasive disease-free survival when combined with endocrine therapy in HR-positive, HER2-negative breast cancer patients, especially those at high risk for recurrence following neoadjuvant chemotherapy.